Back to News
Feb 17, 2026 12:02 PM

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial

Pfizer Inc. (NYSE:PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer.

Pfizer announced that its Braftovi regimen demonstrated a statistically significant improvement in progression-free survival (PFS) for patients with a specific mutation in metastatic colorectal cancer.

Colorectal Cancer Data

Pfizer released topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and Folfiri (fluorouracil, leucovorin, and irinotecan) for previously untreated metastatic colorectal cancer with a BRAF V600E mutation.

This follows the pivotal BREAKWATER trial, where the regimen showed promising results compared to traditional treatments.

In January, Pfizer shared data from Cohort 3 of the BREAKWATER trial, wherein the Braftovi combination regimen cetuximab demonstrated a clinically meaningful and statistically ...